Using #AI to empower employees to take control of their wellness

Elevated stress levels in individuals are reaching epidemic levels in the modern world and are taking a significant toll on industry. We know that stress is a major issue for employees and employers alike, and that work-related stress costs employers up to $300 billion a year; despite that only 36% of employees receive sufficient support to manage stress.

Yet, when we prioritise health and wellbeing, academic evidence proves performance increases and 70% of preventable chronic diseases can be reduced making large savings to healthcare spending and insurance claims.

It’s not all doom and gloom however. We’re proud to announce that based on the success of previous trials with AXA PPP Healthcare, we have completed one of the largest studies on corporate stress and wellness with BNP Paribas, an AXA PPP Healthcare client.


The academic trial with BNP Paribas is part of our focus on transforming the way organisations use data to help employees understand their health, connect the dots and manage their wellbeing by providing personalised interventions based on artificial intelligence (AI).

“By partnering with BioBeats we are taking the next step on our journey to support our employees’ mental and physical health in an objective, scientific and data-rich way. What’s new is how this programme uses technology to provide actionable insights to help change behaviour, encourage stress management and promote a productive lifestyle.” – Ian Mackenzie, Head of Pension & Benefits, BNPP

The 560 BNP Paribas employees on the pilot wore the Microsoft Band 2 to provide BioBeats with various biometric measurements and data continuously throughout the day. Over 60G of data was gathered and analysed in BioBeats’ unique artificial intelligence engine, making it one of the most robust evidence based studies on employee wellbeing. The scientific findings include perceived/actual stress, links between stress and ruminators, and the outcome of breathing as an intervention. The study was under the independent control of Professor Mark Cropley, University of Surrey.

Interested in learning more? Follow our CEO David Plans below.